Normal Delivery Following an Uneventful Pregnancy in a Japanese Acromegalic Patient after Discontinuation of Octreotide Long Acting Release Formulation at an Early Phase of Pregnancy

Endocrine Journal

Takao YOSHIDA¹  Takashi IIZUKA²  Hiroko ITO²  Jun SAITO²  Tatsuro TAKANO²  Tetsuo NISHIKAWA²  Akiko SOYAMA² 

[1] The Department of Obstetrics and Gynecology, Kyoritsu Narashinodai Hospital;Department of Medicine, Yokohama Rosai Hospital

关键词: Acromegaly;    Pregnancy;    Delivery;    Octreotide LAR;   

DOI  :  10.1507/endocrj.53.209

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(21)Cited-By(11)We report a 35-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR treatment for the control of GH excess until discovery of her pregnancy. The patient delivered a healthy boy following an uneventful pregnancy after discontinuing octreotide LAR as soon as possible at the early phase of pregnancy. Despite a substantial maternal-fetal transfer of octreotide, postnatal development was normal at 3 years of age. In almost all previously described cases, octreotide was discontinued after pregnancy was confirmed. No side-effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still-limited number of reported cases treated with octreotide LAR, the potential benefits of octreotide LAR treatment should be weighed carefully against its possible risks.

【 授权许可】

Unknown